Analyst Price Target is $1.35
▲ +55.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cardio Diagnostics in the last 3 months. The average price target is $1.35, with a high forecast of $1.35 and a low forecast of $1.35. The average price target represents a 55.17% upside from the last price of $0.87.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Cardio Diagnostics. This Buy consensus rating has held steady for over two years.
Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois.
Read More